Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer

Ítems similars

• Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
  per: Morán, Teresa, et al.
  Publicat: (2018)
• ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation
  per: Karachaliou, Niki, et al.
  Publicat: (2014)
• Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
  per: Ercan, Dalia, et al.
  Publicat: (2010)
• Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
  per: Zhou, Wenjun, et al.
  Publicat: (2009)
• Discovery of selective irreversible inhibitors for EGFR-T790M
  per: Zhou, Wenjun, et al.
  Publicat: (2010)